NCT06932471招募中3 期
A Multicenter, Single-arm, Open-label Phase III Study to Evaluate Efficacy and Safety of MY008211A Tablets in Patients With PNH and Residual Anemia, Despite Treatment With Anti-C5 Antibody.
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- The proportion of Participants With Sustained Hemoglobin Levels of ≥ 120 g/L in the Absence of Red Blood Cell Transfusions (defined as no red blood cell infusion after D14 to D168)
研究概览
简要总结
The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.
详细描述
This is a multicenter, single-arm, open-label phase III clinical trial. The purpose of this study is to determine whether MY008211A is efficacious and safe for the treatment of PNH patients Who Are Still Anemia After Anti-C5 Antibody Treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%.
- •Stable regimen of anti-C5 antibody treatment for at least 6 months before treatment, and Hb was still < 100 g/L.
- •The average hemoglobin level of at least two tests in 4 months before screening < 100 g/L.
- •The average hemoglobin level of two tests in the central laboratory during screening < 100 g/L.
- •Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.
排除标准
- •Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x10^9/L.
- •History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.
- •Known or suspected hereditary complement deficiency.
- •Previous bone marrow or hematopoietic stem cell transplantation.
- •Previous splenectomy.
- •A history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.
研究组 & 干预措施
MY008211A tablets
Experimental
MY008211A tablets 400mg BID
干预措施: MY008211A tablets (Drug)
结局指标
主要结局
The proportion of Participants With Sustained Hemoglobin Levels of ≥ 120 g/L in the Absence of Red Blood Cell Transfusions (defined as no red blood cell infusion after D14 to D168)
时间窗: between Day 126 and Day 168
The proportion of patients with sustained hemoglobin levels ≥ 120 g/L among those without RBC transfusion.
次要结局
- Change (Expressed as Percentages) in LDH level from baseline(between Day 126 and Day 168)
- Change in reticulocyte count from baseline(between Day 126 and Day 168)
- The proportion of patients without RBC transfusion(between Day 14 and Day 168)
- Change in FACIT-F score from baseline(between Day 126 and Day 168)
- The Clinical BTH Rate(between Day 1 and Day 168)
- The Major Adverse Vascular Events Rate(between Day 1 and Day 168)
- The proportion of subjects with an increase in hemoglobin concentration ≥ 20 g/L from baseline among subjects who do not receive RBC transfusion (defined as no red blood cell infusion after D14 to D168)(between Day 126 and Day 168)
- Change From Baseline in Hemoglobin(between Day 126 and Day 168)
- The proportion of patients with LDH < 1.5 ULN among those without RBC transfusion.(between Day 126 and Day 168)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT06134414Wuhan Createrna Science and Technology Co., Ltd40
已完成
2 期
A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaNCT06050226Wuhan Createrna Science and Technology Co., Ltd34
进行中（未招募）
3 期
Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac EchocardiographyNCT06815627Trust Bio-sonics, Inc.150
招募中
1 期
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNon-hodgkin's LymphomaNCT05623982Sichuan Baili Pharmaceutical Co., Ltd.40
已完成
3 期
Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic GastritisGastritisNCT05024721Hanmi Pharmaceutical Company Limited326